Slide 1: 2025 4Q Earnings Release
CELL BIOTECH Probiotics & Microbiome company 2025 4Q Earnings Release 2026. 04. As a note, it is suggested to use this material only as a reference, as it contains information and data that are subject to changes wi prior notice due to the external audit process, and may cause the actual results to
Slide 2: Revenue up 20.3% to KRW 14.6 billion, operating profit up 30.5%
CELL BIOTECH Revenue up 20.3% to KRW 14.6 billion, operating profit up 30.5% to KRW 3.0 billion Domestic revenue down -0.1%, overseas revenue up 40.3% Duolac brand sales up 2.9% to KRW 6.8 billion, OEM/ODM sales up 63% to KRW 6.7 billion, Raw material sales down -20.7% to KRW 1.1 billion (unit : KRW
Slide 3: 4q revenue KRW 14.6 billion, yoy +20.3%, qoq -4.7%
CELL BIOTECH 4q revenue KRW 14.6 billion, yoy +20.3%, qoq -4.7% Quarterly revenue Full year revenue (unit : KRW mil) (unit : KRW mil) 3
Slide 4: 4q operating profit KRW 3.0 billion, yoy +170%
CELL BIOTECH 4q operating profit KRW 3.0 billion, yoy +170% Net Profit KRW +3.8 bil. Quarterly profit Full year profit (unit : KRW mil) 4
Slide 5: 4q revenue of Duolac brand, OEM/ODM and raw material
CELL BIOTECH 4q revenue of Duolac brand +2.9% to 6.9 KRW bil., OEM/ODM +63% to 6.6 KRW bil., and raw material -20.7% to 1.1 KRW bil. (unit : KRW mil) 5
Slide 6: Business update
Business update CELL BIOTECH Microbiome R&D nee in global export for 12 consecutive 1) Microbiome First-in-Class anticancer pipeline ‘PP-P8’ clinical phase 1 IND submitted (Mar 5, 2021) 1) Cellbiotech's probiotics 'DUOLAC' ranked No. 1 in the world for 12 consecutive years 2) Acquisition European pa
Slide 7: FDA GRAS World's Most Listed
CELL BIOTECH FDA GRAS World’s Most Listed 1) Cellbiotech "11 types of lactic acid bacteria 2) Cellbiotech, Probiotics Leading... Global Leap secured FDA GRAS certification... The World's Largest Holdings" https://www.hankyung.com/article/202402222016i https://www.dailypharm.com/Users/News/NewsVie w.
Slide 8: Now is the Era of K-Probiotics
CELL BIOTECH “Now is the Era of K-Probiotics” – Cellbiotech’s ‘Duolac’ Achieves No. 1 Market Share in Denmark, the Home Country 1) Surpassing Local Brand ‘Lactocare’ --- Assuming the Top Spot with a 46.6% Market Share https://n.news.naver.com/mnews/article/016/000261 4577?sid=101 8
Slide 9: Income statement and statement of financial position
CELL BIOTECH Income statement Statement of financial position (unit : KRW 100 mil., %) (unit : KRW 100 mil., %) 2024 4q 2025 4q 2024 .12 2025 4q Assets 1,304 1,366 Amount Ratio Amount Ratio Current Assets 971.48 1,037 Revenue 121.6 100.0 146.3 100.0 Non current Assets 332.49 329 Gross profit 88.5 72